the effect of pilocarpine 1% eye drop on the relative improvement of presbyopia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240325061363N1

Enrollment

Registered

2024-04-20

Start date

2024-04-06

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

presbyopia. Presbyopia

Interventions

Intervention 1: Intervention group: sterile eye drops Pilocarpine 1% (Sina darou company) every morning, one drop in each eye for one month. Intervention 2: Control group: sterile eye drops Tearlose (

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients aged 40-60 years Suffering from presbyopia Uncorrected near visual acuity: 20/40 to 20/100

Exclusion criteria

Exclusion criteria: Eye diseases (including glaucoma, cataracts, amblyopia, high myopia, eye trauma, congenital pupil abnormalities, corneal opacity, intraocular surgeries) Severe sensitivity and side effects to eye drops Taking drugs that interact with pilocarpine

Design outcomes

Primary

Measure	Time frame
Uncorrected near visual acuity and uncorrected distance visual acuity. Timepoint: Before the intervention, 20 minutes later, one hour and six hours later, as well as on the 14th and 30th days. Method of measurement: Snellen chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad hosein Abutorabi zarchi

Yazd University of Medical Sciences

m.h.abootorabi222@gmail.com+98 35 3820 0782

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026